摘要
准确评价淋巴结转移与否关系到对肿瘤患者的分期和预后的判断。目前对淋巴结良恶性诊断的主要依据为淋巴结的大小和形态,正常大小的转移性淋巴结很可能被遗漏,增大的淋巴结是良性增生还是恶性转移也很难鉴别。近年来随着MR特异性对比剂,特别是MR靶向淋巴结对比剂的发展,MR淋巴成像(MR Lymphography,MRL)显示了极为诱人的前景。该文主要介绍MR淋巴靶向对比剂的研究进展。
The accurate evaluation of tumor metastases in prognosis in cancer patients. At present, differentiating between lymph nodes is important for tumor staging and malignant and benign lymph nodes still rely only on the size and shape of the lymph nodes. Thus, small metastases in normal size lymph nodes can be missed, and it is difficult to differentiate enlarged nodes （benign hyperplasia versus malignant disease）. Recently, with the advancement of the MR specificity contrast agents, especially MR lymphotropic contrast medium, MR lymphography has shown attractive perspective. This summary mainly introduces the progress of MR targeted contrast agents in lymphography.
出处
《生物医学工程学进展》
CAS
2011年第4期206-209,共4页
Progress in Biomedical Engineering
